Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Ipsen

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

              Contact the Supplier

              Lead Product(s): Palovarotene

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2020

              Details:

              Ipsen to conduct further assessment of the complete data set and work with the regulatory authorities, based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses.

              PharmaCompass__DigitalAd